|May 16, 2002
|AUDIO WEB REPLAY OF HEMISPHERX'S MAY 16, 2002 CONFERENCE CALL AVAILABLE ON COMPANY'S WEBSITE
|Philadelphia, PA, Thursday, May 16, 2002: Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today that an audio web replay of the Company’s conference call on Thursday May 16, 2002 at 10:30 AM will be available on the Company’s website from May 16, 2002 through May 24, 2002.
During the conference call, the Company discussed its results for the first quarter ending March 30th 2002. It also discussed recent developments in the treatment of HIV AIDS as these developments relate to the Company’s technology. Additionally, the Company described preparations it is making regarding the upcoming international AIDS conference in Barcelona Spain during the first week in July 2002.
In order to listen to the replay, please go to www.Hemispherx.net and follow the link.
Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company's Web site at www.hemispherx.net
William A. Carter, M.D., CEO & Chairman, Hemispherx Biopharma, Inc.
Dianne Will, Investor Relations, (518) 398-6222, Fax: (518) 398-6223
Robert Giordano, Institutional Investors, MRB, (212) 230-1727, Fax: (212) 230-1734
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.